Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 503 Results

Page 45 of 51« First «...10 20 30...43 444546 47...50...»Last »

April 15, 2014

DBV Technologies Announces Topline Financial Results for First Three Months 2014

April 9, 2014

DBV Technologies and CEA conclude a scientific cooperation to investigate epigenetic modulation in epicutaneous immunotherapy

April 7, 2014

DBV Technologies Announces Creation of US Subsidiary and Appoints Ms. Susanna Mesa as Vice President of Finance, US Investor Relations & Strategy

March 31, 2014

Additional Contribution to the Liquidity Agreement with Natixis

March 25, 2014

DBV Announces Data Presentations for EPIT at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2014

March 17, 2014

DBV Technologies Reports Full Year 2013 Financial Results and Provides VIPES Update

March 4, 2014

Presentation and Publication of Research at AAAAI Demonstrates EPITTM’s Ability to rebalance the Immune System and Induce a Disease-Modifying Effect

February 18, 2014

DBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn’s Disease

January 30, 2014

DBV Technologies Reports Full Year 2013 Topline Financial Results

December 17, 2013

DBV provides 2013 year-end summary and news flow guidance for 2014

Page 45 of 51« First «...10 20 30...43 444546 47...50...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Cookies Policy

Scroll to Top